Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials

Autor: Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi

Publikováno v: Rheumatology and Therapy, Vol 10, Iss 1, Pp 161-185 (2022)

Abstract Introduction We conducted a post hoc analysis of efficacy and safety of filgotinib stratified by estimated radiographic progression rate before baseline (BL) in patients with rheumatoid arthritis (RA) who had inadequate response to methotrex

Externí odkaz: https://doaj.org/article/5ad3c011326f47e39cc3a991b6b2f59f

Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4.

Autor: Tanaka Y; First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Fukuoka, Japan., Matsubara T; Department of Orthopedics, Matsubara Mayflower Hospital, Hyogo, Japan., Atsumi T; Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan., Amano K; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Ishiguro N; Aichi Developmental Disability Center, Aichi, Japan., Hirata S; Department of Clinical Immunology and Rheumatology, Hiroshima University, Hiroshima, Japan., Yamaoka K; Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan., Combe BG; Rheumatology Department, CHU Montpellier, Montpellier University, Montpellier, France., Nash P; Griffith University of Queensland, Brisbane, Queensland, Australia., Genovese M; Gilead Sciences, Inc., Foster City, USA., Pechonkina A; Gilead Sciences, Inc., Foster City, USA., Liu J; Gilead Sciences, Inc., Foster City, USA., Kondo A; Gilead Sciences K.K., Tokyo, Japan., Fukada H; Gilead Sciences K.K., Tokyo, Japan., Leonardis F; Galapagos NV, Mechelen, Belgium., Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, and Saitama Medical University, Saitama, Japan.

Publikováno v: Modern rheumatology [Mod Rheumatol] 2024 Nov 07. Date of Electronic Publication: 2024 Nov 07.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.

Autor: Tanaka, Yoshiya, Matsubara, Tsukasa, Atsumi, Tatsuya, Amano, Koichi, Ishiguro, Naoki, Sugiyama, Eiji, Yamaoka, Kunihiro, Combe, Bernard G., Kivitz, Alan J., Sang-Cheol Bae, Keystone, Edward C., Nash, Peter, Genovese, Mark, Matzkies, Franziska, Bartok, Beatrix, Pechonkina, Alena, Akira Kondo, Lei Ye, Qi Gong, Tasset, Chantal

Publikováno v: Modern Rheumatology; Jul2023, Vol. 33 Issue 4, p668-679, 12p

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study (Rheumatology and Therapy, (2022), 10.1007/s40744-022-00498-x)

Autor: Combe, Bernard G., Tanaka, Yoshiya, Buch, Maya H., Nash, Peter, Burmester, Gerd R., Kivitz, Alan J., Bartok, Beatrix, Pechonkina, Alena, Xia, Katrina, Emoto, Kahaku, Kano, Shungo, Hendrikx, Thijs K., Landewé, Robert B. M., Aletaha, Daniel

Publikováno v: Rheumatology and therapy, 10(1), 71-72

In this article the legend for Fig. 5 was inadvertently with error, the legend for Fig. 5 should have appeared as shown below.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::5df95e89fb8e75082a1da9c045983545
https://pure.amc.nl/en/publications/correction(e4a92aaf-1e59-4bcf-a64e-840d8a4fb6ab).html